NCT07036458

To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects

An Open-label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C Epaminurad in Healthy Male Subjects

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: JW Pharmaceutical · Industry
• Sex: Male
• Age: 30 Years – 65 Years
• Healthy volunteers: Accepted

Summary

To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects

Detailed description

The following blood, urine and faecal samples will be collected, and assessments performed, at specified time points

Conditions

• Healthy Male Adults

Interventions

Type	Name	Description
DRUG	14C Epaminurad Oral Solution	Subjects will receive a single administration of 14C Epaminurad Oral Solution

Timeline

• Start date: 2025-08-22
• Primary completion: 2025-09-30
• Completion: 2026-01-09
• First posted: 2025-06-25
• Last updated: 2025-09-09

Locations

1 site across 1 country: United Kingdom